Moderna (NASDAQ: MRNA) shares closed trading on Friday, June 26, with a powerful surge of 12%. This is just the tip of the iceberg: over the past six months, the American biotech giant's stock has risen by a staggering 125.51%. The ascent began from lows near $46 recorded in early June, and now the market is questioning—how justified is this momentum?
The key catalyst was the unanimous decision of the FDA's Vaccines and Related Biological Products Advisory Committee. On June 18, experts (9 out of 9) supported a positive risk/benefit assessment for the drug mFLUSIVA (mRNA-1010)—a seasonal influenza vaccine for individuals over 50. Such unanimous verdicts in biotech are rare. This has dramatically reduced regulatory uncertainty ahead of the final FDA decision scheduled for August 5. If approved, mFLUSIVA would become the first seasonal influenza vaccine based on mRNA technology in the United States.
Wall Street remains cautious despite euphoria
Piper Sandler analysts raised their price target for MRNA to $77, while Jefferies experts increased their forecast to $53, maintaining a "hold" rating. However, the median stock forecast stands at just $43.45—significantly below current quotes. This indicates deep skepticism from the professional community: out of the last 75 insider transactions, the vast majority were sales. Analysts do not expect significant revenue from influenza vaccine sales before 2027.
Not just vaccines: restructuring and oncology
In parallel, Moderna reorganized its business around three areas: vaccines, oncology, and rare diseases. This news lifted quotes by approximately 6.3%. On Science Day, June 25, the company presented an expanded development portfolio, including programs for in vivo CAR-T and T-cell engineering for oncology and autoimmune diseases. Additionally, plans to invest in production in Germany, including sites that BioNTech intends to close, led to MRNA stock rising by 8–12% over several sessions. The market perceived this move as a long-term bet on increasing capacity ahead of a wave of new launches in 2027–2028.
My analysis: The combination of factors—a regulatory breakthrough, diversification into oncology, and aggressive expansion of the production base—forms a powerful foundation for further growth. However, the current imbalance between the stock price and the analyst consensus forecast indicates a high speculative overhang. Investors should be prepared for volatility, especially ahead of the FDA decision on August 5. If mFLUSIVA receives approval, we will see a new round of rally, but without it, the correction could be as sharp as the surge.